Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jinming Yu

Showing results (581-590 of 779) with videos related to

Pageof 78
Sort By:
Cancer Letters|December 19, 2025
Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancerXiangjiao Meng, Nan Bi, Jun Wang, et al.
Oncotarget|December 8, 2017
A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese populationHuihui Li, Chunxiao Chang, Yuhong Shang, et al.
Translational Lung Cancer Research|September 21, 2020
<sup>18</sup>F-RGD PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancerLi Li, Wei Zhao, Xiaorong Sun, et al.
Oncotarget|January 26, 2017
The impact of intratumoral metabolic heterogeneity on postoperative recurrence and survival in resectable esophageal squamous cell carcinomaXinzhe Dong, Xiaorong Sun, Xianguang Zhao, et al.
Oncotarget|January 12, 2017
Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC)Qianqian Zhu, Yanan Sun, Yingying Cui, et al.
Translational Oncology|October 8, 2024
Unraveling the mechanisms of RECQL4-mediated cervical cancer progression through the PI3K/AKT pathwayWen Huo, Yiheng Huang, Baoqinq Tian, et al.
Medcomm|November 21, 2025
Preclinical Characterization of SDFZ-8, a Highly Potent HDAC1 Inhibitor, for Cancer ImmunotherapyYi Zhou, Jintong Du, Xue Li, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 26, 2024
[<sup>18</sup>F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical TrialYinjun Dong, Zhendan Wang, Xinying Hu, et al.
Radiology|August 8, 2023
FAPI Compared with FDG PET/CT for Diagnosis of Primary and Metastatic Lung CancerYuchun Wei, Li Ma, Pei Li, et al.
Frontiers in Nutrition|March 16, 2026
The relationship between triglyceride-glucose index, triglyceride-glucose-body mass index, and the severity of hepatic steatosis and liver fibrosis in patients with MASLD: a cross-sectional studyXingye Wu, Jiacheng Mo, Jinming Yu, et al.
Pageof 78

Showing results (581-590 of 779) with videos related to

Sort By:
Pageof 78
Cancer Letters|December 19, 2025
Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancerXiangjiao Meng, Nan Bi, Jun Wang, et al.
Oncotarget|December 8, 2017
A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese populationHuihui Li, Chunxiao Chang, Yuhong Shang, et al.
Translational Lung Cancer Research|September 21, 2020
<sup>18</sup>F-RGD PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancerLi Li, Wei Zhao, Xiaorong Sun, et al.
Oncotarget|January 26, 2017
The impact of intratumoral metabolic heterogeneity on postoperative recurrence and survival in resectable esophageal squamous cell carcinomaXinzhe Dong, Xiaorong Sun, Xianguang Zhao, et al.
Oncotarget|January 12, 2017
Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC)Qianqian Zhu, Yanan Sun, Yingying Cui, et al.
Translational Oncology|October 8, 2024
Unraveling the mechanisms of RECQL4-mediated cervical cancer progression through the PI3K/AKT pathwayWen Huo, Yiheng Huang, Baoqinq Tian, et al.
Medcomm|November 21, 2025
Preclinical Characterization of SDFZ-8, a Highly Potent HDAC1 Inhibitor, for Cancer ImmunotherapyYi Zhou, Jintong Du, Xue Li, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 26, 2024
[<sup>18</sup>F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical TrialYinjun Dong, Zhendan Wang, Xinying Hu, et al.
Radiology|August 8, 2023
FAPI Compared with FDG PET/CT for Diagnosis of Primary and Metastatic Lung CancerYuchun Wei, Li Ma, Pei Li, et al.
Frontiers in Nutrition|March 16, 2026
The relationship between triglyceride-glucose index, triglyceride-glucose-body mass index, and the severity of hepatic steatosis and liver fibrosis in patients with MASLD: a cross-sectional studyXingye Wu, Jiacheng Mo, Jinming Yu, et al.
Pageof 78